Research
Hormonal
Pharmacotherapy is recommended for postmenopausal females and males aged 50+ who have had a previous hip or vertebral fracture, or have a 10-year major osteoporotic fracture risk of 20% or more.
If you are over 50 and have had a hip or vertebral fracture, or have a high 10-year fracture risk (20% or more), you should strongly consider pharmacotherapy. This is a strong recommendation based on high-certainty evidence. Your doctor will help you choose the right medication based on your specific risks and preferences.
StrongSupportsHIGH confidence
We recommend initiating pharmacotherapy in postmenopausal females and males aged ≥ 50 yr who a. have had previous hip, vertebra or ≥ 2 osteoporosis-related fractures OR b. have a 10-yr major osteoporotic fracture risk ≥ 20% OR c. are aged ≥ 70 yr and have a T-score ≤ –2.5.
Why this rating
Strong recommendation with high-certainty evidence for females.
Source
Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update
Suzanne N. Morin et al. · Canadian Medical Association Journal · 2023
DOI 10.1503/cmaj.221647
clinical_guidelineCited 180×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Functional and balance training performed at least twice weekly significantly reduces the rate of falls in adults over 50, with high-certainty evidence supporting this intervention for fracture prevention.Strong
- For individuals consuming a balanced diet, calcium and vitamin D supplementation provides little to no beneficial or detrimental effect on fracture prevention.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →